





Lipid remodelling in hepatocyte proliferation  
and hepatocellular carcinoma 
 
Zoe Hall1,2,*, Davide Chiarugi3, Evelina Charidemou1, Jack Leslie4, Emma Scott4, Luca 
Pelligrinet1, Michael Allison5, Gabriele Mocciaro1, Quentin M. Anstee4,6, Gerard I. Evan1, 
Matthew Hoare5, 7, Antonio Vidal-Puig3, Fiona Oakley4, Michele Vacca1,3,#,* & Julian L. 
Griffin1,2 ,#, * 
 
1 Department of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, 
Cambridge, United Kingdom; 2 Biomolecular Medicine, Division of Systems Medicine, Department of 
Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom; 3 
Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, 
United Kingdom; 4 Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, 
Newcastle upon Tyne, United Kingdom; 5 Department of Medicine, Addenbrooke’s Hospital, 
Cambridge Biomedical Research Centre, Cambridge, United Kingdom; 6 Newcastle NIHR Biomedical 
Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United 
Kingdom; 7 CRUK Cambridge Institute, Robinson Way, Cambridge, United Kingdom 





liver regeneration; cancer metabolism; mass spectrometry imaging; HCC; phosphatidylcholine 
2 
 
Corresponding Author Contact Information: 
Dr Zoe Hall; Biomolecular Medicine, Department of Metabolism, Digestion and Reproduction, Sir 
Alexander Fleming Building, South Kensington Campus, Imperial College London, Exhibition Road, 
London SW7 2AZ, United Kingdom; zoe.hall@imperial.ac.uk; Tel.: +44 (0) 7709 844249. 
Dr Michele Vacca; Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic 
Science, Box 289, Addenbrooke’s Hospital, Cambridge  CB2 0QQ, United Kingdom; 
mv400@medschl.cam.ac.uk; Tel.: +44 (0) 7474 301485 
Professor Julian L. Griffin; Biomolecular Medicine, Department of Metabolism, Digestion and 
Reproduction, Sir Alexander Fleming Building, South Kensington Campus, Imperial College London, 
Exhibition Road, London SW7 2AZ, United Kingdom; julian.griffin@imperial.ac.uk;  Tel: +44 (0)20 
7594 3220. 
 
List of Abbreviations: 
HCC – Hepatocellular carcinoma 
PC – Phosphatidylcholine 
NAFLD – non-alcoholic fatty liver disease 
NASH – non-alcoholic steatohepatitis 
CTNNB1 -  -catenin 
PH - partial hepatectomy  
CCl4 - carbon tetrachloride 
PB - phenobarbital  
DEN - N-diethylnitrosamine 
HFD - high fat diet 
LC-MS – liquid chromatography mass spectrometry 
MSI - mass spectrometry imaging 
PCA - principal components analysis  
PLS-DA - partial least squares discriminant analysis  
OPLS-DA -orthogonal projection to latent structures discriminant analysis  
3 
 
SEM – standard error of the mean 
PCNA - proliferating cell nuclear antigen 
NGS - Next Generation Sequencing  
IPA - Ingenuity Pathway  
FBA - flux balance analysis 
GEM - genome-scale metabolic model  
PPARα - nuclear receptor peroxisome proliferator-activated receptor α 
MUFA - monounsaturated fatty acid 
PUFA - polyunsaturated fatty acid  
SFA – saturated fatty acid 
PE - phosphatidylethanolamine  
TAG – triacylglyceride 
FFA  - free fatty acid 
SM - sphingomyelin  
TCA - citric acid cycle  
ACSL - long chain acyl-CoA synthetase 
SCD – stearoyl coA desaturatase 
 
Financial Support: 
J.L.G., Z.H. and M.V. are funded by the Medical Research Council (MRC grant MC UP A90 1006 & MC 
PC 13030). J.L.G. and Z.H. are supported by the Imperial Biomedical Research Centre, NIHR. M.A., 
A.V-P., F.O., Q.M.A. and M.V. are members of the EPoS consortium, which is funded by the Horizon 
2020 Framework Program of the European Union under Grant Agreement 634413. F.O. is supported 
by MRC program grants (MR/K0019494/1 and MR/R023026/1). J.L is supported by MRC PhD 
studentship and a CRUK program grant (C18342/A23390). M.V. and A.V-P. are supported by MRC 
MDU and MRC DMC (MC UU 12012/2). Q.M.A. received additional research support from The Liver 
Research Trust and is a Newcastle NIHR Biomedical Research Centre investigator. M.A., M.V., A.V-P. 
and J.L.G. received research support from the Evelyn Trust and the NIHR Cambridge Biomedical 




Background & Aims: Hepatocytes undergo profound metabolic rewiring when primed to proliferate 
during compensatory regeneration and in hepatocellular carcinoma (HCC). However, the metabolic 
control of these processes is not fully understood. In order to capture the metabolic signature of 
proliferating hepatocytes, we applied state-of-the-art systems biology approaches to models of liver 
regeneration, pharmacologically- and genetically-activated cell proliferation, and HCC.  
Approach & Results: Integrating metabolomics, lipidomics and transcriptomics, we link changes in 
the lipidome of proliferating hepatocytes to altered metabolic pathways including lipogenesis, fatty 
acid desaturation, and generation of phosphatidylcholine (PC). We confirm this altered lipid 
signature in human HCC and show a positive correlation of monounsaturated-PC with hallmarks of 
cell proliferation and hepatic carcinogenesis.  
Conclusion: Overall, we demonstrate that specific lipid metabolic pathways are coherently altered 
when hepatocytes switch to proliferation. These represent a source of targets for the development 







The liver is characterised by an impressive regenerative potential following cell loss or the activation 
of direct hyperplasia programs. Compared to other organs and tissues, where the regeneration is 
mainly driven by stem cell precursors, liver regeneration often requires the proliferation of 
differentiated hepatocytes to compensate for cell loss (1). Aberrant hepatocyte proliferation in 
chronic liver disease is also a driving cause of hepatocellular carcinoma (HCC), one of the leading 
causes of cancer-related deaths world-wide. HCC typically occurs on a background of chronic liver 
disease, with risk factors including viral or autoimmune hepatitis, chronic alcohol abuse, and non-
alcoholic fatty liver disease (NAFLD) (2, 3). HCC is genetically heterogeneous, with mutations in the 
TERT promoter, TP53 and CTNNB1 (-catenin) most frequently reported (4). Whilst more commonly 
preceded by cirrhosis, HCC may also develop directly in a context of non-alcoholic steatohepatitis 
(NASH) (5). The pathogenesis of fatty liver-associated HCC is complex and the focus of intense 
research. Some of the contributing factors are thought to include hepatic lipotoxicity, oxidative 
stress, modulation of nuclear receptors, stellate cell activation, and the chronic activation of wound-
healing processes including inflammatory and immune responses, together producing a carcinogenic 
milieu (6-8).  
One of the hallmarks of HCC, and cancer in general, is cellular proliferation. In order to fuel this 
proliferation, there is a higher demand for macromolecular biosynthesis, for structural and energy 
purposes. There is also a need to evade the consequences of a deleterious environment (e.g. 
hypoxia and reactive oxygen species), and thus extensive metabolic reprogramming occurs in cancer 
cells (9-12). Increased uptake and utilisation of glucose via glycolysis (the Warburg effect), increased 
fatty acid uptake and increased de novo lipid synthesis have all been described (13, 14).  It is widely 
accepted that many molecular and metabolic mechanisms are partially conserved between liver 
regeneration and HCC (15). Despite the importance for normal wound healing and its relevance to 
HCC, very little has been reported on the metabolic alterations of regenerating hepatocytes, 
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particularly with respect to lipid-related pathways (16-19). Characterising the metabolic remodelling 
that hepatocytes undergo during compensatory regeneration and in HCC is thus crucial to identify 
metabolic pathways that relate to cell proliferation in general and, more specifically, to HCC growth. 
To bridge this gap, we used a multi-omics approach to characterise the metabolic rewiring of 
hepatocytes in proliferation, for a range of mouse models of liver regeneration, hepatic hyperplasia 
and HCC. Overall our findings shed new light on the lipid-related metabolic adaptations occurring in 
cell proliferation and survival, highlighting a coherent role of lipid composition and lipid pathways in 




All data are from male C57BL/6 mice purchased from Charles River (Edinburgh, U.K.) or MRC Harwell 
Institute (Harwell, U.K.). Mice were housed in a temperature-controlled room (21°C) with a 12-hour 
light/dark cycle with free access to diet and water. The UK Home Office and the Bioethics 
Committees of the Universities of Cambridge and Newcastle approved all animal procedures. Mice 
were fed on a chow diet (Safe Diets, Code ds-105) unless otherwise stated in the description of the 
different procedures. 
Partial hepatectomy: Twelve week-old mice underwent two-thirds partial hepatectomy (PH) 
procedure, according to the method of Higgins and Anderson (20). The left lateral and median lobes 
were completely excised. Mice were sacrificed 3 days after hepatectomy to mimic the peak of 
proliferation. Resected livers were used as time 0 control for gene and lipid analyses to perform 
paired analyses (N = 5 per group). 
Carbon tetrachloride studies: Sixteen week old mice were maintained as specific pathogen free 
according to the FELASA Guidelines and underwent IP injection of 2 L/g body weight of CCl4 : olive 
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oil (1:1 v/v) mix, or olive oil only (N = 3 per group). Mice were humanely culled under isofluorane 
terminal anaesthesia, 3 days after the IP injection.  
Phenobarbital: Pharmacologically-induced hepatocyte proliferation was induced in mice (18-20 
weeks old) by the administration of 0.1% phenobarbital (PB) in drinking water for 72 hr, before 
humane culling (N = 5 or 6 per group).  
N-Diethylnitrosamine-induced HCC: Two week-old mice were given a single IP injection of N-
diethylnitrosamine (DEN) (30 mg/kg) and were maintained on a chow diet for a further 40 weeks (N 
= 4) or a high fat diet (HFD; D12331, Research Diets Inc with 58 kcal% fat and sucrose) for a further 
30 weeks (N = 6). Mice fed a HFD were also given 42.1 g/L of sugar (18.9 g glucose and 23.0 g of 
fructose) in their drinking water.  
Oncogenic model of HCC:  In a genetic mouse model of HCC, activation of Kras and Myc oncogenes in 
sporadic hepatocytes and subsequent tumour formation, was achieved in KrasG12D-RosaMycER 
animals (21, 22) i.v. delivery of AAV8-TBG-CRE virus (Vector Biolabs, Malvern, PA) and daily i.p. 
tamoxifen (Sigma Aldrich, St. Louis, MO) delivery for 2 weeks.  
Human samples 
Seven patients undergoing liver transplantation for HCC, developing in a cirrhotic fatty liver (NASH, 
N=2; alcohol-related liver disease, N=5; Table S1) background were recruited at Addenbrooke’s 
Hospital, Cambridge (Division of Hepatology). All the patients had HCC and tumour-free background 
liver tissue collected. Histological analysis was performed by the Department of Pathology, 
Addenbrooke’s Hospital, and snap-frozen tissue was stored at -80 °C for research purposes in the 
Cambridge Human Tissue Bank. The study protocol was approved by the Office for Research Ethics 
Committees of Northern Ireland (LREC 16/NI/0196). All patients gave their informed consent for the 
use of clinical data and samples for scientific research purposes. The principles of the Declaration of 
Helsinki were followed. 
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Lipid and metabolite profiling  
Lipids and metabolites were extracted from tissue using the Folch method (23). Briefly, 30 mg of 
liver tissue was homogenised in chloroform: methanol (2:1, 1 mL) using a TissueLyser (Qiagen Ltd., 
Manchester, UK). Deionised water (400 L) was added, and the samples well mixed. Separation of 
the aqueous and organic layers was carried out following centrifugation (12,000 g, 10 min). The 
resulting organic and aqueous extracts were dried-down under nitrogen or in a vacuum centrifuge, 
respectively and stored at -80 oC until analysis. 
The organic lipid-containing layer was analysed by untargeted liquid chromatography-mass 
spectrometry (LC-MS) using an Accela Autosampler coupled to a LTQ Orbitrap EliteTM (Thermo Fisher 
Scientific, Hemel Hempstead, UK). Lipid identification was performed by accurate mass using an in-
house database. The aqueous fraction was analysed by targeted LC-MS/MS using UHPLC+ coupled to 
a TSQ Quantiva mass spectrometer (Thermo Fisher Scientific, Hemel Hempstead, UK). The mass 
spectrometer was operated in SRM mode; transitions and source conditions for each metabolite are 
summarised in Table S2. Further method details are available in the supporting information. 
RNA extraction 
RNA was isolated using miRNAeasy Mini Kits (Qiagen), according to the manufacturer’s instructions. 
Samples were stored at - 80°C prior to use. All reagents and consumables used were nuclease free 
(molecular biology grade). RNA purity (A260/A280 > 1.80) and concentration were determined using 
Nanodrop (Thermo Fisher scientific, Delaware USA). RNA integrity was studied using the 2100 
Bioanalyzer System (Agilent) and RNA 6000 Nano Kit. 
Whole transcriptome amplification and RNA sequencing 
RNA from tissues of murine (2 g RNA) or human (1 g RNA) were used to generate barcoded 
sequencing libraries using the TruSeq® Stranded mRNA Library Preparation Kit (Illumina) or TruSeq 
Stranded total RNA Library Preparation Kit for murine and human liver, respectively, following 
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manufacturer’s instructions. The sequencing libraries were normalized for concentration and 
combined into pools. The libraries were sequenced using an Illumina HiSeq 4000 instrument at 
single-end 50bp (SE50) or NextSeq 500 at single-end 75bp (SE75), equivalent to > 20 million reads 
per sample. 
Bioinformatics functional analyses 
Pathway enrichment was investigated for differentially expressed genes within groups using 
Ingenuity Pathway Analysis (IPA, Qiagen). Canonical pathways, Bio-functions, and Upstream 
Regulators analyses were generated by imputing “biologically significant” genes [statistically 
significant (q score < 0.05) and with -0.378 < log2 (fold change) > 0.378]. Significantly (p < 0.05) 
enriched hits were then ranked in terms of activation status (Z-score). We additionally used IPA to 
compare the pathways significantly (p < 0.05) enriched in all the datasets, with predicted 
activation/inhibition in all the datasets, and with -1 < Z-score > 1 in at least one comparison, and 
same direction of modulation.  
Flux balance analysis 
Using R software packages SBMLR , BiGGR  and sybil , we performed flux balance analysis (FBA) on 
HepatoNet1 , a manually reconstructed tissue-specific genome-scale metabolic model (GEM) for the 
hepatocyte. To perform FBA on our models, we first determined metabolic fluxes in the ‘’normal’’ 
hepatocyte. Then, we mimicked the observed transcriptional changes for differentially expressed 
genes in each of the experimental set-ups (PH, CCl4 and DEN/HFD), by increasing or decreasing the 
metabolic fluxes of the reactions catalysed by enzymes corresponding to the up- or down-regulated 







Metabolic remodelling during proliferation and cancer   
In order to elucidate the metabolic adaptations occurring in normal hepatocytes when they switch 
to proliferate, we used murine studies of compensatory regeneration following partial hepatectomy 
(PH) or acute toxic damage induced by carbon tetrachloride (CCl4), and direct hyperplasia induced by 
phenobarbital (PB, an activator of the constitutive active androstane receptor (CAR). Seventy-two 
hours after the challenge, all the experimental models showed a substantial proportion of 
hepatocytes expressing the proliferating cell nuclear antigen (PCNA), suggesting that proliferative 
programs were activated in these cells at the time-point chosen (Figure S1A-C). Following CCl4-
treatment, there was extensive necrosis noted in pericentral areas, accompanied by increased 
inflammatory infiltrates (Figure S1B), whereas PB-treatment resulted in mild to moderate steatosis 
(Figure S1C), as shown before (24). To study proliferation in the context of HCC on a “lean” or fatty 
liver background, mice exposed to N-diethylnitrosamine (DEN) were maintained on either chow or 
high fat diet (HFD) (25).  
Using Next Generation Sequencing (NGS) and Ingenuity Pathway Analysis (IPA), we studied the 
biological processes modulated in compensatory regeneration (PH and CCl4) and HCC (DEN/HFD). As 
expected, we identified upregulation of pathways/bio-functions and upstream regulators associated 
with the regulation of cell cycle, survival, migration, invasion, and chromatin and extracellular matrix 
remodelling (Supporting file 1). In addition, upregulation of inflammation, angiogenesis, and other 
processes relevant for growth of multiple cancer types were identified. 
IPA also predicted dysregulation of multiple canonical pathways and bio-functions involved in 
metabolism (Figure 1A), including the suppression of amino acid catabolism and inhibition of the 
nuclear receptor peroxisome proliferator-activated receptor α (PPARα; the master transcriptional 
regulator of hepatic fatty acid oxidation). Increased carbohydrate metabolism, and processes 
favouring the accumulation of lipids and cholesterol (which are needed for fueling proliferation; 
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Figure 1A) were also featured. Increased lipid synthesis was predicted in PH and DEN/HFD only, 
whilst increased oxidative stress featured only in models of hepatotoxicity and cancer (CCl4 and 
DEN/HFD). Furthermore, suppression of fatty acid oxidation (and associated pathways) 
predominantly occurred in the CCl4 model, but did not reach significance in PH and DEN/HFD 
models. 
Next, we used IPA to study the activation status of upstream regulators (Figure 1B-1C, Supporting 
file 1). Interestingly, there was predicted activation of a number of nuclear receptors and their co-
activators (e.g. Nrip1, Pxr, Rara, Ar, Vdr and the phospholipid sensor Lrh1 - previously described to 
control liver regeneration and HCC (8)); and of other crucial modulators of glucose and lipid 
metabolism. Predicted inhibited upstream regulators included nuclear receptors such as Hnf4a, the 
farsenoid X receptor (Fxr), as well as a plethora of other proteins involved in glucose and lipid 
metabolism, and negatively associated with cell proliferation and cancer (such as Pten, Hnf1a/b, 
Foxa1, Acox1 and Apoe). These results suggest that the rewiring of hepatocyte metabolism is 
orchestrated at transcriptional level, and that multiple factors are coherently modulated to allow the 
switch toward proliferation. In particular, changes to lipid and amino acid metabolism were 
indicated. 
Proliferating hepatocytes are characterised by distinctive lipid composition 
To investigate changes to lipid metabolism, we performed lipidomics experiments on models of 
compensatory regeneration (PH and CCl4) and direct hyperplasia (PB). Proliferating liver tissue had 
distinct lipid profiles to their corresponding control group for all three models (Figure 2A, Figure S2, 
Supporting file 2). Using orthogonal projection to latent structures discriminant analysis (OPLS-DA; 
R2 = 0.89, Q2 = 0.82, p < 0.001), we found that samples undergoing compensatory regeneration had 
increased monounsaturated fatty acid (MUFA)-containing phosphatidylcholine (PC), 
phosphatidylethanolamine (PE) 40:6, short chain triacylglycerides (TAG) and free cholesterol, with a 
decrease in polyunsaturated fatty acid (PUFA)-containing PCs and sphingomyelin (SM) 40:1 (Figure 
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2B). On the other hand, direct hyperplasia following PB-treatment revealed a general increase in 
TAGs and cholesteryl esters (CE), increased MUFA-containing PC(36:1), and a decrease in PC(38:6) 
and PC(32:0), compared to control (OPLS-DA; R2 = 0.88, Q2 = 0.87, p < 0.01; Figure 2C). The increase 
in TAGs and cholesterol during proliferation is consistent with the transcriptional pathway analysis, 
which featured net accumulation of both lipid classes and suppressed  fatty acid oxidation. However, 
the most striking observation was the significant increase in MUFA-containing PCs, that was 
consistent throughout the models of liver proliferation (Figure 2D). These results suggest that the 
increase in MUFA-containing PCs is a common event in hepatocyte proliferation, independent from 
the strategy used to switch on the proliferative program.  
Monounsaturated phosphatidylcholine accumulates in HCC tumours  
We next studied how the lipidome of HCC compares to adjacent non-tumour tissue in the DEN 
mouse models (in mice challenged with chow diet, or HFD to study hepatocellular carcinogenesis in 
the context of fatty liver). According to the lipid profiles measured using LC-MS (Supporting file 2) 
and analysed using principal components analysis (PCA), the four groups appeared to be well 
discriminated in terms of lipid composition, with samples split by diet in the first principal 
component (Figure 3A). A direct comparison of all tumour samples with non-tumour revealed that 
compared to their adjacent tissue, tumours had increased TAGs, CEs and MUFA-PC, and a decrease 
in PUFA-PC (OPLS-DA; R2 = 0.87, Q2 = 0.71, p = 0.02; Figure 3B). The levels of MUFA-PC were 
significantly increased in tumours for both DEN-exposed dietary groups at paired analysis (Figure 
3C). 
Despite accurately dissecting HCC tumours macroscopically, there still might be the risk of 
contamination of tumors with areas of normal tissue (and vice-versa). To independently confirm our 
data and overcome this potential limitation of whole-tissue lipid extractions, we used mass 
spectrometry imaging (MSI). MSI allows the spatial mapping of lipids across a tissue slice, and is 
therefore ideally suited for cancer research (12). Applying MSI to tissue sections, we confirmed a 
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striking accumulation of MUFA-PC and decrease in SM(40:1) in tumours of both chow and HFD 
models (Figure 3D). Furthermore, MSI highlighted the zonation of particular lipids across the non-
tumour adjacent tissue, as we have shown previously (26) (Figure 3E).  
As a further model of HCC, we employed a genetically-tractable mouse model of hepatocyte 
proliferation and spontaneous tumorigenesis. Concommitant activation of Ras and Myc, known 
oncogenes mutated or amplified in human HCC, resulted in rapid hepatocyte proliferation, and 
widespread formation of small and highly proliferative neoplasms. Taking advantage of the rapid and 
synchronous tumorigenesis in this model and the spatial lipid mapping potential of MSI, we 
investigated the lipidomic signature of these early cancerous lesions and of the surrounding tumor-
free tissue. Similar to the DEN-induced tumours, we found an increase in MUFA-PC, particularly 
PC(34:1), in neoplastic lesions (Figure 3F), with documentable increased proliferation (Figure S1D).  
Having established the major lipid profile changes in mouse models of proliferation and cancer, we 
sought to confirm whether these changes are also relevant in human HCC. Using a cohort of human 
HCC samples on a fatty liver background, we compared the lipid profiles in HCC compared to their 
paired non-tumour tissue (Supporting file 2, Figure S3A). This revealed an increase in MUFA-PC and 
decreased plasmalogens (HCC  vs. HCC tissue; Figure 4A). Whilst the change in plasmalogens was not 
consistently recapitulated in the animal models (Figure S3), the increased MUFA-PC was in 
agreement with all the mouse models of proliferation and cancer. MSI was used to confirm these 
changes, revealing a particularly striking accumulation of MUFA-containing PC(36:1) in HCC (Figure 
4B). These data further confirm that the increase in MUFA-containing PC is a crucial event, 
associated with the proliferative switch of hepatocytes and with hepatocellular carcinogenesis.  
Metabolic reprogramming in liver regeneration and cancer 
Next, we measured a set of core aqueous metabolites (Supporting file 3). Metabolite profiles 
measured during liver regeneration (PH and CCl4-treated) were clearly distinguishable from their 
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corresponding control profiles, whilst PB-treatment did not result in a significantly different 
metabolite profile compared to control (Figure S4A). We then went on to identify the metabolites 
responsible for differentiating liver regeneration from control groups (OPLS-DA; R2 = 0.97, Q2 = 0.87, 
p < 0.01; Figure S4B). Overall liver regeneration following PH or CCl4-injury resulted in significantly 
increased levels of many amino acids (e.g. glutamate, proline, leucine), increased metabolites 
involved in phospholipid biosynthesis (e.g CDP-choline), and nucleotide intermediates (ribose-5-
phosphate, cytidine).   
For the metabolite profiles of DEN-treated mice, we found that the samples were differentiated by 
diet on the first principal component (Figure S4C). The DEN/chow tumour samples were separated 
from non-tumour in the second principal component however the separation between tumour and 
non-tumour was poor for DEN/HFD, when looking at aqueous metabolite profiles alone (Figure S4C). 
Further study of the DEN/chow group (OPLS-DA; R2 = 0.98, Q2 = 0.90, p = 0.02; Figure S4D) suggested 
that tumours had increased amino acids (e.g. glutamate and glutamine) and citric acid cycle (TCA) 
intermediates (malate, succinate, citrate, fumarate), compared to non-tumour tissue. Tumours were 
also characterised by decreased β-hydroxybutyrate (Figure S4D) – a by-product of mitochondrial β-
oxidation, in agreement with the inhibited action of PPAR  from the transcriptomics pathway 
analysis.  
Lastly, we measured the aqueous metabolite profiles for human HCC and associated non-tumour 
tissue. We found several amino acids to be significantly increased in HCC tumours, including lysine, 
histidine and alanine; whereas aspartate was significantly reduced (Supporting file 3). Critically, 
similar to the liver regeneration studies, there was a significant increase in CDP-choline in HCC 
versus non-tumour tissue (Figure 4C).  
Overall our metabolomics results are in-line with proliferating cells undergoing metabolic rewiring to 
sustain a higher demand for macromolecular biosynthesis of amino acids, phospholipids and 
nucleotides, and increased energy production. In particular, proliferating cells have an increased 
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need for glucogenic amino acids (such as glutamine/glutamate) in order to supply nitrogen and 
carbon for biosynthesis and to produce ATP via the TCA cycle. The observed increase in amino acids 
may be driven, at least in part, by the suppression of their catabolism, as highlighted by 
transcriptional pathway analysis.  
Metabolic fluxes are directed towards increased phospholipid synthesis 
Metabolomics and lipidomics experiments demonstrated an increase in MUFA-containing PC and 
CDP-choline during liver regeneration and cancer. Using gene expression data from the same PH, 
CCl4 and DEN/HFD samples, we performed a targeted analysis of the main metabolic pathways 
involved in the generation and homeostasis of MUFA-PC (Figure 5), using differential gene 
expression patterns. Where multiple isoforms of a gene are involved in a reaction (e.g. Dgat1, 
Dgat2), we considered only those that were significantly different in at least one of the three 
models. We validated our findings in silico, by performing flux balance analysis (FBA) on a genome-
scale metabolic model (GEM) of the hepatocyte (Table S3). 
Starting with catabolic pathways, and in agreement with the pathway analysis featuring suppressed 
PPARα activity (Figure 1B), there was an overall trend across the three groups for decreased 
expression of genes and reduced metabolic flux for mitochondrial (Acads, Acadsb, Cpt2) and 
peroxisomal -oxidation (Acox1, Acox3) pathways (Figure 5A, Table S3). Activation of FFA to fatty 
acyl-CoA prior to oxidation is carried out by the long chain acyl-CoA synthetases (ACSL). Whilst 
expression for Acsl1 was consistently decreased across the groups, that of Acsl4 and Acsl5 were 
consistently increased. Though not exclusive, these three enzymes have been shown to have 
substrate preference for MUFA, PUFA and saturated fatty acids (SFA), respectively (27, 28). It is 
therefore tempting to speculate that during times of rapid proliferation, whilst -oxidation is 
reduced overall, PUFA and/or SFA are oxidised in preference to MUFA.  
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Turning to anabolic pathways (Figure 5B), we found increased gene expression and/or metabolic flux 
for lipogenic genes (e.g. Acaca, Acly), and the elongation (Elovl6) and desaturation (Scd1/2) of 
palmitic acid, FFA(16:0), to FFA(18:1), particularly in the PH and DEN/HFD models. Fatty acids can 
then be incorporated into PC via the Land’s cycle (Lpcat). Metabolic fluxes suggest that the Land’s 
cycle is working towards the synthesis of phospholipids (Table S3). 
PC is also formed de novo via the Kennedy pathway (Figure 5C). This pathway was upregulated in 
proliferation and cancer, through increased gene expression of Chka and availability of substrate 
(e.g. choline). Furthermore, breakdown of SM can also contribute phosphocholine, a substrate which 
can enter the Kennedy pathway (Figure 5C). This is supported by increased gene expression of 
Smpd3, and MSI which showed a dramatic decrease of SM(40:1) in tumours (Figure 3D). FBA 
confirmed that the Kennedy pathway is driven towards increased PC synthesis in hepatocyte 
proliferation and cancer (Table S3). 
In addition, following the imposed up/down regulations of the fluxes through -oxidation and 
lipogenesis, the whole metabolic network reacts by enhancing lipid synthesis and modulating flux 
through both glycolysis (e.g. upregulated commitment and rate-limiting steps catalysed by 
hexokinase, Hk, and phosphofructokinase, Pfk) and the TCA cycle (upregulated at the level of citrate 
synthase, Cs; downregulated at malate dehydrogenase, Mdh, and -ketoglutarate dehydrogenase, 
Ogdh, steps; Table S3), thus working as an anaplerotic pathway for de novo lipogenesis.  
MUFA lipids are correlated with genetic markers of hepatocellular carcinoma  
Having identified potential lipid metabolic pathways affected by proliferation and cancer, we next 
evaluated gene/metabolite correlations in tumour-only groups to see if their concentration 
correlated with the proliferative behaviour. Within DEN/HFD tumours, we assessed correlation of 
total MUFA-PC with related lipid metabolic genes, and with known diagnostic and prognostic 
markers of HCC. We found a strong positive correlation between total MUFA-PC and Chka, Acly, 
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Scd2, Lpl, Acsl4 gene expression and choline, CDP-choline metabolites (Figure S5). This suggests that 
the increase in MUFA-PC in tumours is closely linked to de novo lipogenesis, desaturation by Scd and 
synthesis of PC by the Kennedy pathway. On the other hand, a strong negative correlation was 
observed between MUFA-PC and Acsl1, Pemt, Dgat2 and Acad gene expression. In addition, MUFA-
PC was positively correlated to proliferation markers (Ki67, Ccne1, Ccnd1, Ccne2, Ccnd2), and HCC 
diagnostic markers (Afp, Spp1), thus suggesting the importance of these lipids for the proliferative 
status of HCC (Figure S5).  
Lastly, we performed RNA sequencing on human HCC tumours to assess whether similar correlations 
would also be found. We performed a Spearman’s rank correlation analysis for the three groups of 
PC (SFA, MUFA, PUFA) and related lipid genes, with gene expression pertaining to known markers of 
HCC and proliferation. There were several clusters identified in the correlation matrix for HCC 
tumours, whereas no clusters and few significant correlations could be calculated within the non-
tumour group (Figure 6A, Figure S6). Similar to the DEN/HFD model, we found distinct associations 
for MUFA-PC in tumours, compared to SFA- and PUFA-containing PC. Considering the lipid-related 
pathways, MUFA-PC was positively correlated with gene expression for ACLY, ACACA, ELOVL6, SCD, 
and ACSL4; and with CDP-choline metabolite levels. There was positive correlation of SFA-PC with 
LAMB1, ICAM1, TGFB1 (markers of EMT, amongst other functions), and CCND2. As previously 
described in murine samples, MUFA-PC was associated with expression of proliferation and cell cycle 
markers (CCNE2, CCNA2, CCNB2, PCNA, MYC), and several clinical diganostic and/or prognostic 
markers of HCC (e.g. AFP, SPP1) (Figure 6A, Figure 6B).   
Taken together, our data suggest that hepatocyte proliferation in HCC is linked to: i) enhanced de 
novo lipogenesis; ii) increased SCD-mediated desaturation of fatty acyl chains; iii) reduced -
oxidation; and iv) increased de novo synthesis of PC through the Kennedy pathway. This has the net 
result of increasing the MUFA pool, and MUFA-PC in particular. MUFA-PC may therefore have use as 
a marker of proliferation, and warrants further large-scale studies to assess the suitability of these 
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lipids for clinical application as diagnostic and prognostic biomarkers of HCC or, for use of MUFA-PC 
anabolic pathways as targets for treatment. 
 
DISCUSSION 
Growing evidence suggests that the modulation of cell metabolism could be a good strategy to 
ameliorate cell proliferation in cancer. It is of great importance, therefore, to unravel the complex 
metabolic adaptations arising in cancer cells, when they switch to uncontrolled proliferation. This 
may lead to identifying novel pharmacological targets and potential diagnostic or prognositc 
biomarkers. Several metabolomics studies on HCC have been performed to date (29-32). Here we 
show for the first time an integrated systems biology dataset (lipids, aqueous metabolites and RNA 
sequencing), studying the reprogramming of lipid metabolism in multiple models of liver 
regeneration, direct hepatic hyperplasia, and in murine and fatty liver-associated human HCC.  
The most striking difference amongst models of proliferation was that PB-treated mice developed a 
substantially higher hepatic TAG content than other models, as expected (33). In the murine models 
of HCC, there were distinct differences in the TAG composition, with a greater increase in short-
chain TAGs in tumours of the HFD model, compared to chow (Figure S7). This highlights diet-specific 
changes in hepatic metabolism, in the context of HCC. Importantly, we were also able to identify the 
changes in lipid metabolism occurring in proliferating hepatocytes, independently from the 
challenge that activates the proliferative program, or of the surrounding microenvironment.  
Specifically, an increase in MUFA-PC was measured by lipidomics, and confirmed by MSI in cancer, 
for all the models. We integrated data from lipidomics, metabolomics and transcriptomics to link 
these changes in lipid content to specific pathways. These included increased lipogenesis, fatty acyl 
desaturation, de novo synthesis of PC, PC remodelling and decreased -oxidation. We also show for 
the first time that levels of MUFA-PC are strongly correlated with proliferation markers, cell cycle 
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control and other known genetic markers of HCC in both mouse and human tumours. Increased 
MUFA in the lipidome may confer several advantages to highly proliferative cancer cells and has 
been described before (34-36). One such advantage would be to prevent an accumulation of 
palmitic acid from increased lipogenesis, which otherwise could trigger endoplasmic reticulum (ER) 
stress and apoptoic signalling pathways (37). Furthermore, a reduction in saturated phospholipids 
was reported to alter membrane fluidity in HCC cells, resulting in improved uptake of glucose and 
increased metastatic abilities (38). Reducing PUFA in the PC fraction could also help proliferating 
cells to ameliorate the production of pro-inflammatory eicosanoids via phospholipase action, 
thereby promoting cell survival and the priming of proliferative programs. The decreased 
plasmalogens observed in HCC, compared to non-tumour tissue, is also of interest. A subset of these 
lipids are thought to play a protective role against oxidative damage and depleted levels of 
circulating plasmalogens have been linked to HCC (decreased in serum of HCC patients compared to 
control group) and type 2 diabetes (32, 39-41).  
Targeting lipid metabolism is increasingly attracting interest as a therapeutic strategy for HCC (42). 
There is a growing body of evidence suggesting that inhibition of the desaturation and elongation of 
fatty acids offers an alternative to suppressing de novo synthesis (37, 43-45). Our study suggests that 
the change in the abundance of multiple lipid-related metabolic genes is associated with the 
development and progression of human HCC and warrant further study to evaluate their potential as 
drug targets. Since hepatic MUFA-PC was closely correlated with proliferation and other markers of 
HCC, this further has the potential to become a new prognostic marker and enable improved patient 
stratification. 
Finally, our study revealed that much of the lipid reprogramming in cancer cells was also 
recapitulated in mouse models of liver regeneration and direct hepatic hyperplasia, suggesting that 
these mechanisms are not necessarily cancer-specific but more broadly associated with hepatocyte 
proliferation. This has important implications to better understand the role of lipid metabolism in 
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the pathophysiological events linking NASH-cirrhosis to HCC but also in terms of personalised 
medicine. Given that hepatocyte proliferation is impaired in advanced phases of chronic liver 
disease, our study suggests that the choice of metabolic target for the treatment of HCC might need 
careful evaluation, particularly when associated with liver resection. Overall, our study has shed new 
light on metabolic adaptions of proliferating hepatocytes to enrich MUFA-PC, opening several new 




1. Malato Y, Naqvi S, Schürmann N, Ng R, Wang B, Zape J, Kay MA, et al. Fate tracing of mature 
hepatocytes in mouse liver homeostasis and regeneration. The Journal of Clinical Investigation 
2011;121:4850-4860. 
2. Allaire M, Nault JC. Type 2 diabetes–associated hepatocellular carcinoma: A molecular 
profile. Clinical Liver Disease 2016;8:53-58. 
3. Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences 
for treatment. Oncologist 2010;15 Suppl 4:14-22. 
4. Cancer Genome Atlas Research Network. Electronic address wbe, Cancer Genome Atlas 
Research N. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. 
Cell 2017;169:1327-1341.e1323. 
5. Teilhet C, Morvan D, Joubert-Zakeyh J, Biesse A-S, Pereira B, Massoulier S, Dechelotte P, et 
al. Specificities of Human Hepatocellular Carcinoma Developed on Non-Alcoholic Fatty Liver Disease 
in Absence of Cirrhosis Revealed by Tissue Extracts ¹H-NMR Spectroscopy. Metabolites 2017;7:49. 
6. Vacca M, Allison M, Griffin JL, Vidal-Puig A. Fatty acid and glucose sensors in hepatic lipid 
metabolism: Implications in NAFLD. Seminars in Liver Disease 2015;35:250-261. 
7. Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current 
concepts and future challenges. Nature Reviews Gastroenterology & Hepatology 2019. 
8. Vacca M, Degirolamo C, Massafra V, Polimeno L, Mariani-Costantini R, Palasciano G, 
Moschetta A. Nuclear receptors in regenerating liver and hepatocellular carcinoma. Molecular and 
Cellular Endocrinology 2013;368:108-119. 
9. Griffin JL, Lehtimäki KK, Valonen PK, Gröhn OHJ, Kettunen MI, Ylä-Herttuala S, Pitkänen A, et 
al. Assignment of 1H Nuclear Magnetic Resonance Visible Polyunsaturated Fatty Acids in BT4C 
Gliomas Undergoing Ganciclovir-Thymidine Kinase Gene Therapy-induced Programmed Cell Death. 
Cancer Res 2003;63:3195-3201. 
10. Hilvo M, Denkert C, Lehtinen L, Muller B, Brockmoller S, Seppanen-Laakso T, Budczies J, et al. 
Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism 
in breast cancer progression. Cancer Res 2011;71:3236-3245. 
11. Gaude E, Frezza C. Tissue-specific and convergent metabolic transformation of cancer 
correlates with metastatic potential and patient survival. Nature Communications 2016;7:13041. 
12. Hall Z, Ament Z, Wilson CH, Burkhart DL, Ashmore T, Koulman A, Littlewood T, et al. Myc 
expression drives aberrant lipid metabolism in lung cancer. Cancer Research 2016;76:4608-4618. 
21 
 
13. Baenke F, Peck B, Miess H, Schulze A. Hooked on fat: the role of lipid synthesis in cancer 
metabolism and tumour development. Dis Model Mech 2013;6:1353-1363. 
14. Rohrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer 
2016;16:732-749. 
15. Vacca M, Degirolamo C, Massafra V, Polimeno L, Mariani-Costantini R, Palasciano G, 
Moschetta A. Nuclear receptors in regenerating liver and hepatocellular carcinoma. Mol Cell 
Endocrinol 2013;368:108-119. 
16. Caldez MJ, Van Hul N, Koh HWL, Teo XQ, Fan JJ, Tan PY, Dewhurst MR, et al. Metabolic 
Remodeling during Liver Regeneration. Developmental Cell 2018;47:425-438.e425. 
17. Huang J, Rudnick DA. Elucidating the metabolic regulation of liver regeneration. The 
American journal of pathology 2014;184:309-321. 
18. Piccinin E, Peres C, Bellafante E, Ducheix S, Pinto C, Villani G, Moschetta A. Hepatic 
peroxisome proliferator-activated receptor gamma coactivator 1beta drives mitochondrial and 
anabolic signatures that contribute to hepatocellular carcinoma progression in mice. Hepatology 
2018;67:884-898. 
19. Vacca M, D'Amore S, Graziano G, D'Orazio A, Cariello M, Massafra V, Salvatore L, et al. 
Clustering Nuclear Receptors in Liver Regeneration Identifies Candidate Modulators of Hepatocyte 
Proliferation and Hepatocarcinoma. PLOS ONE 2014;9:e104449. 
20. Higgins GM. Experimental pathology of the liver. Restoration of the liver of the white rat 
following partial surgical removal. AMA Arch Pathol 1931;12:186-202. 
21. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, Brown-Swigart L, et al. 
Distinct thresholds govern Myc's biological output in vivo. Cancer cell 2008;14:447-457. 
22. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T, et al. Analysis of 
lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 
2001;15:3243-3248. 
23. Folch J, Lees M, Stanley GHS. A simple method for the isolation and purification of total 
lipids from animal tissues. Journal of Biological Chemistry 1957;226:497-509. 
24. Massart J, Begriche K, Moreau C, Fromenty B. Role of nonalcoholic fatty liver disease as risk 
factor for drug-induced hepatotoxicity. Journal of clinical and translational research 2017;3:212-232. 
25. Santos NP, Colaco AA, Oliveira PA. Animal models as a tool in hepatocellular carcinoma 
research: A Review. Tumour Biol 2017;39:1010428317695923. 
26. Hall Z, Bond NJ, Ashmore T, Sanders F, Ament Z, Wang X, Murray AJ, et al. Lipid zonation and 
phospholipid remodeling in nonalcoholic fatty liver disease. Hepatology 2017;65:1165-1180. 
27. Grevengoed TJ, Klett EL, Coleman RA. Acyl-CoA metabolism and partitioning. Annual review 
of nutrition 2014;34:1-30. 
28. Yan S, Yang X-F, Liu H-L, Fu N, Ouyang Y, Qing K. Long-chain acyl-CoA synthetase in fatty acid 
metabolism involved in liver and other diseases: an update. World journal of gastroenterology 
2015;21:3492-3498. 
29. Huang Q, Tan Y, Yin P, Ye G, Gao P, Lu X, Wang H, et al. Metabolic characterization of 
hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res 2013;73:4992-5002. 
30. Muir K, Hazim A, He Y, Peyressatre M, Kim DY, Song X, Beretta L. Proteomic and lipidomic 
signatures of lipid metabolism in NASH-associated hepatocellular carcinoma. Cancer Res 
2013;73:4722-4731. 
31. Patterson AD, Maurhofer O, Beyoglu D, Lanz C, Krausz KW, Pabst T, Gonzalez FJ, et al. 
Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid 
profiling. Cancer Res 2011;71:6590-6600. 
32. Lu Y, Chen J, Huang C, Li N, Zou L, Chia SE, Chen S, et al. Comparison of hepatic and serum 
lipid signatures in hepatocellular carcinoma patients leads to the discovery of diagnostic and 
prognostic biomarkers. Oncotarget 2018;9:5032-5043. 




34. Guo S, Wang Y, Zhou D, Li Z. Significantly increased monounsaturated lipids relative to 
polyunsaturated lipids in six types of cancer microenvironment are observed by mass spectrometry 
imaging. Sci Rep 2014;4:5959. 
35. Bansal S, Berk M, Alkhouri N, Partrick DA, Fung JJ, Feldstein A. Stearoyl-CoA desaturase plays 
an important role in proliferation and chemoresistance in human hepatocellular carcinoma. J Surg 
Res 2014;186:29-38. 
36. Budhu A, Roessler S, Zhao X, Yu Z, Forgues M, Ji J, Karoly E, et al. Integrated metabolite and 
gene expression profiles identify lipid biomarkers associated with progression of hepatocellular 
carcinoma and patient outcomes. Gastroenterology 2013;144:1066-1075 e1061. 
37. Peck B, Schulze A. Lipid desaturation - the next step in targeting lipogenesis in cancer? FEBS J 
2016;283:2767-2778. 
38. Lin L, Ding Y, Wang Y, Wang Z, Yin X, Yan G, Zhang L, et al. Functional lipidomics: Palmitic acid 
impairs hepatocellular carcinoma development by modulating membrane fluidity and glucose 
metabolism. Hepatology 2017;66:432-448. 
39. Jang JE, Park HS, Yoo HJ, Baek IJ, Yoon JE, Ko MS, Kim AR, et al. Protective role of 
endogenous plasmalogens against hepatic steatosis and steatohepatitis in mice. Hepatology 
2017;66:416-431. 
40. Dean JM, Lodhi IJ. Structural and functional roles of ether lipids. Protein Cell 2018;9:196-206. 
41. Oresic M, Simell S, Sysi-Aho M, Näntö-Salonen K, Seppänen-Laakso T, Parikka V, Katajamaa 
M, et al. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children 
who later progress to type 1 diabetes. The Journal of experimental medicine 2008;205:2975-2984. 
42. Lally JSV, Ghoshal S, DePeralta DK, Moaven O, Wei L, Masia R, Erstad DJ, et al. Inhibition of 
Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and 
Hepatocellular Carcinoma. Cell Metabolism 2019;29:174-182.e175. 
43. Peck B, Schug ZT, Zhang Q, Dankworth B, Jones DT, Smethurst E, Patel R, et al. Inhibition of 
fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised 
environments. Cancer Metab 2016;4:6. 
44. Su Y-C, Feng Y-H, Wu H-T, Huang Y-S, Tung C-L, Wu P, Chang C-J, et al. Elovl6 is a negative 
clinical predictor for liver cancer and knockdown of Elovl6 reduces murine liver cancer progression. 
Scientific Reports 2018;8:6586. 
45. Shibasaki Y, Horikawa M, Ikegami K, Kiuchi R, Takeda M, Hiraide T, Morita Y, et al. Stearate-
to-palmitate ratio modulates endoplasmic reticulum stress and cell apoptosis in non-B non-C 
hepatoma cells. Cancer Sci 2018;109:1110-1120. 
 
AUTHOR CONTRIBUTIONS 
ZH, MV and JLG conceived and designed the study and wrote the manuscript. MV, JL, ES, LP, QMA, 
GIE, AVP, and FO designed and performed the animal experiments. MA and MH provided human 
samples and data. ZH,  EC and GM performed lipidomics and metabolomics analyses. DC, ZH and MV 
performed the statistical, bioinformatics and pathway analyses. All the authors provided useful 





The authors are indebted to the following, who supported the activities presented in this 
manuscript: Dr Olivier Govaere (Newcastle University); Dr James West (University of Cambridge); the 
Disease Model Core, the Genomics and Transcriptomics Core, the Histology Core and the Imaging 
Core at Metabolic Research Laboratories, University of Cambridge; staff in the Genomics Core 
Facility (GCF) and the Bioinformatic Support Unit (BSU; Peter Leary & Simon J. Cockell) at Newcastle 
University. The human samples come from the Human Research Tissue Bank of the Cambridge 
University Hospitals, which is supported by the NIHR Cambridge Biomedical Research Centre.  
 
DATA AVAILABILITY 
All the data are available upon request. NGS data in this manuscript has been deposited on GEO data 




Figure 1. Pathway enrichment analysis of the transcriptome reveals changes to metabolism of 
lipids and amino acids in proliferation and cancer. Enrichment analysis for canonical pathways (CP) 
and bio-functions (BF) was performed on differentially expressed genes for the PH (N = 5), CCl4 (N = 
3) and DEN/HFD (N = 4) models (A). Comparative analysis of predicted upstream regulators (UR) for 
PH (N = 5), CCl4 (N = 3) and DEN/HFD (N = 4) models, based on pathways significantly (p < 0.05) 
enriched and with a predicted activation/inhibition (predicted activation status: Z-score) (B). 
“Network-like” graphical representation of the interaction between upstream regulators and the 
differentially modulated pathways they control (blue: downregulated; orange: upregulated) in the 
three models (C). Full list of modulated pathways in Supporting File 1 (BF: n44; CP: n15; UR: n191). 
Figure 2. Mice undergoing hepatocyte proliferation have characteristically different hepatic lipid 
profiles to controls. Lipid profiles were measured by liquid chromatography mass spectrometry (LC-
MS), and compared using partial least squares discriminant analysis (PLS-DA) (A). Orthogonal (O)PLS-
DA models and their associated S-plots were constructed to compare liver regeneration (PH and 
CCl4) groups versus control (B), and direct hyperplasia PB-treated versus control (C). There was 
consistently an increase in monounsaturated (MUFA)-containing phosphatidylcholines (PC) in 
proliferating liver (D). Paired data are represented as spaghetti plots; non-paired data show mean ± 
SEM (*** p < 0.001, ** p < 0.01, * p < 0.05). PH experiment (before = 5, after = 5); CCl4 experiment 
(control = 3, treated = 3); PB experiment (control = 5, treated = 6).  
Figure 3. MUFA-containing PC is increased in tumours for different models of HCC. HCC was 
induced by DEN-exposure in WT mice, fed a chow or high fat diet (HFD). LC-MS based lipidomics data 
were used to perform principal components analysis (PCA) and to construct PLS-DA models, wherein 
good separation of the different groups was achieved (A). OPLS-DA was used to compare tumour-
containing groups versus non-tumour groups (B). There was an increase in MUFA-containing PC in 
tumour for DEN/HFD and DEN/chow mice (C). Paired data are shown as spagetti plots (*** p < 0.001, 
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** p < 0.01, * p < 0.05). DEN/chow: N = 4 per group; DEN/HFD: N = 6 per group. Mass spectrometry 
imaging (MSI) revealed that MUFA-containing PC is increased, and SM(40:1) is decreased, in tumours 
for three different models of HCC. Adjacent H&E stained sections are shown, alongside single ion 
intensity images (D). An overlay of three lipid distributions, highlighting the differentiation of tumour 
from adjacent, zonated tissue (representative sample from the DEN/chow group is shown) (E). The 
spatial distribution of PC(34:1) in control tamoxifen-treated liver is contrasted to that following 
oncogenic activation of MYC (F). In control, PC(34:1) follows a zonal pattern correpsonding to 
periportal areas, as reported previously; following activation of MYC, the zonation is altered with 
PC(34:1) co-localising with neoplastic lesions.  
Figure 4. Lipid and metabolite changes in human hepatocellular carcinoma. Increased MUFA-PC 
and decreased plasmalogens were found in HCC tumours, compared to non-tumour (A). MSI shows 
increased MUFA-containing PC(36:1) in human HCC, compared to adjacent non-tumour tissue (B). 
Aqueous metabolomics experiments revealed a striking increase in CDP-choline in tumours, 
compared to non-tumour (C). Paired data are shown;*** p < 0.001, ** p < 0.01, * p < 0.05); N = 7. 
Figure 5. Multi-omics reveals widespread modulation of lipid metabolism in liver proliferation and 
cancer. Gene expression and metabolic fluxes were examined for pathways involved in -oxidation 
(A), de novo lipogenesis (B) and synthesis of PC by the Kennedy pathway (C). For lipid catabolism, 
genes of interest included fatty acid activation (Acsl family), carnitine shuttle (Cpt2), mitochondrial 
(Acad family) and peroxisomal (Acox family) -oxidation, and ketogenesis (Aacs). Acetyl-coA from -
oxidation can enter the TCA cycle, which generates citrate for lipid synthesis. Fatty acids are 
synthesised by de novo lipogenesis (Acly, Acaca, Fasn), and subsequently elongated (Elovl6) and 
desaturated (Scd). They can then be esterified into complex lipids, such as phosphatidylcholine (PC) 
by the Land’s cycle (Lpcat). PC is also formed de novo by the Kennedy pathway (Chka, Pcyt1, Chpt1). 
Dietary lipids (hydrolysis of TAGs by Lpl) and sphingomyelin (breakdown by Smdp3) can also feed 
into the Kennedy pathway. Finally, phosphatidylethanolamine (PE) can be converted to PC by Pemt. 
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Predicted metabolic flux for the PH model is indicated by colour of the enzyme names (red = 
upregulated; blue = downregulated) (A). Individual gene expression log2 fold changes after PH (N = 
5), CCl4-treatment (N = 3) and in DEN/HFD (N = 4) tumours are shown in adjacent heatmaps. *** p < 
0.001, ** p < 0.01, * p < 0.05, adjusted for false discovery using Benjamin-Hochberg approach. 
Legend for heat map shown at bottom. Supporting file 4 and Table S3 have further details on the 
metabolic flux analysis.  
Figure 6. MUFA-PC is correlated with proliferation, cell cycle and markers of HCC in humans. 
Heatmap of correlation matrix (Spearman’s rank correlation coefficient, 95 % C.I., p < 0.05 adjusted 
using Benjamin-Hochberg method) for gene expression and differentially unsaturated PCs in human 
HCC tumours (N = 7). Metabolites are in yellow text; lipid-related genes in green and HCC-associated 
genes in blue. Two main clusters were identified. The first shows a positive correlation of SFA-PC to 
several genes associated with HCC. The second cluster links MUFA-PC to proliferation and further 
HCC-associated genes. In addition, MUFA-PC was positively correlated with lipid metabolic genes 
ELOVL6, SCD, ACSL4, ACACA and metabolite CDP-choline (A). Individual patient correlations for 
PCNA, CCNE2 and CCNB2 gene expression with MUFA-PC concentration, and TGFB1 with SFA-PC (B).  
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